Three Nevirapine-Based Treatments for HIV in China
Author Information
Author(s): Li Taisheng, Dai Yi, Kuang Jiqiu, Jiang Jingmei, Han Yang, Qiu Zhifeng, Xie Jing, Zuo Lingyan, Li Yanling
Primary Institution: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Hypothesis
The study aimed to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection.
Conclusion
The study found that 3TC+d4T and 3TC+AZT are effective combinations for HIV treatment, while AZT+ddI+NVP showed poor virological response, especially in patients with higher CD4 counts.
Supporting Evidence
- The regimen of AZT+ddI+NVP produced poor virological response especially in patients with CD4 count more than 200/ul.
- 68.2% of patients in group B and 69% in group C achieved suppression of plasma HIV-1 RNA to less than 50 copies/ml.
- Hepatotoxicity was significantly associated with higher CD4 baseline and HCV-Ab positive status.
Takeaway
This study looked at three different treatments for HIV and found that two of them worked better than the third one.
Methodology
A prospective, multicenter study where 198 HIV-1 positive patients were randomized into three treatment groups and monitored for viral and immunologic responses.
Potential Biases
Potential bias due to the study being conducted in a specific population and the randomization process.
Limitations
The study was limited to antiretroviral-naïve patients and may not be generalizable to those with prior treatment.
Participant Demographics
Participants were adult HIV-1 positive patients with CD4 counts between 100/ul and 350/ul.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%CI: 1.106–3.973
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website